**Supplemental Table 2.** Characteristics and incidence of irAE between immunosuppressant-treated and non-immunosuppressant-treated patients in the COVID-19 positive group.

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Immunosuppressant-treated group** **(n=13)** | **Non-immuno-suppressant-treated group (n=33)** | ***p*-Value** |
| **Age, median (range), year** | 69 (50 - 91) | 67 (41 - 84) | 0.52 |
| **Gender, n (%)** |  |  | 0.73 |
|  Male | 5 (38.5) | 10 (30.3) |  |
|  Female | 8 (61.5) | 23 (69.7) |  |
| **Ethnicity, n (%)** |  |  | 0.23 |
|  White | 8 (61.5) | 27 (81.8) |  |
|  African American | 1 (7.7) | 2 (6.1) |  |
|  Other | 4 (30.8) | 4 (12.1) |  |
| **ECOG score, n (%)** |  |  | 1.00 |
|  0-1 | 13 (100.0) | 32 (97.0) |  |
|  2 and beyond | 0 (0.0) | 1 (3.0) |  |
| **Type of ICI, n (%)** |  |  | 0.51 |
|  Pembrolizumab | 7 (53.8) | 22 (66.7) |  |
|  Atezolizumab | 2 (15.4) | 3 (9.1) |  |
|  Nivolumab | 2 (15.4) | 4 (12.1) |  |
|  Durvalumab | 1 (7.7) | 2 (6.1) |  |
|  Ipilimumab + Nivolumab | 1 (7.7) | 2 (6.1) |  |
| **Time to COVID-19 infection, median (range), days** | 147 (-31 – 1,732) \* | 139 (29 – 1,882) | 0.42 |
| **Incidence of irAE** |  |  |  |
|  All grades | 2 (15.4) | 12 (36.4) | 0.29 |
|  Grade 3-4 | 2 (15.4) | 3 (9.1) | 0.61 |
| **Death related to COVID-19, n (%)** | 6 (46.1) | 3 (9.1%) | 0.01 |

*Abbreviations:* irAE, immune-related adverse events; COVID-19, coronavirus disease 2019; ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor

\* Four patients had COVID-19 infection 31 days, 30 days, 23 days, and 21 days prior to the initiation of ICI therapy, respectively.